top of page
png440x100.png){kind=logo}
In less than 5 minutes, learn all about kidney diseases and treatment options
Sparsentan for IgA Nephropathy
Worldwide, IgA nephropathy (IgAN) is a leading cause of chronic kidney disease and end-stage kidney disease. Luckily, new treatment options are becoming available. You can learn more about sparsentan (Filspari) here:
Inaxaplin for APOL1-mediated Kidney Disease
APOL1 genetic variants are linked to an increased risk of kidney disease in people of African descent. Exciting new therapies targeting APOL1-associated kidney disease are on the horizon. Learn more about Inaxaplin here:
bottom of page